They may also slow the progression of diabetes-related nephropathy, making them valuable in comprehensive diabetes management (10)
At WellLife Medical Centers, we understand that true wellness extends beyond just the number on the scale
This reduces the risk of experiencing side effects
Safety Profile The most common adverse events documented across retatrutide results data were gastrointestinal in nature, with incidence increasing at higher doses: Nausea: 6-31% (dose-dependent), primarily during escalation periods Diarrhea: 6-25%, generally mild to moderate Vomiting: 0-16%, occurring mainly in the first weeks of each dose increase Decreased appetite: 3-19%, which contributed to the weight reduction effect Constipation: 3-12%, consistent with GLP-1 receptor-mediated gastric slowing Serious adverse events were rare across all cohorts
Sodiumglucose cotransporter 2 inhibitors (SGLT2is) have shown kidney-protective effects in large kidney-dedicated outcome trials [4,5,6], and dedicated kidney outcome trials on glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1ras) are awaited